Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories, Inc. (NASDAQ: MLAB) is described in its public communications as a global leader in the design and manufacture of life science tools and critical quality control solutions. Its news flow reflects this focus, with regular updates related to regulated applications in the pharmaceutical, healthcare, and medical device industries.
Visitors to this MLAB news page can review company-issued press releases covering financial results, divisional performance, and capital structure decisions. Mesa frequently announces quarterly results for its four divisions—Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics—highlighting revenues, organic and core organic revenues growth, and commentary on factors such as tariffs, foreign exchange, and geographic trends.
The news stream also includes dividend declarations, where the Board of Directors approves a regular quarterly dividend on Mesa’s common stock, along with record and payment dates. In addition, Mesa issues releases about investor conference participation and healthcare conference presentations, providing context for how management communicates with the investment community.
Another recurring theme in Mesa’s news is financing and balance sheet activity, such as the execution of strategic financing plans, use of its credit facility, and repayment or settlement of convertible notes. These items offer insight into how the company manages its capital structure alongside its operating performance.
By following this page, readers can access a chronological view of Mesa’s official announcements, including earnings releases, dividend decisions, conference appearances, and financing updates, all drawn from the company’s own disclosures.
Mesa Laboratories (NASDAQ:MLAB) has announced a quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record as of August 29, 2025.
Mesa Labs is a global leader specializing in life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Their products and services help ensure product integrity, enhance patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB), a global leader in life science tools and quality control solutions, has scheduled its first quarter fiscal year 2026 financial results announcement for August 5, 2025, at 8:00 A.M. Eastern time.
The company specializes in designing and manufacturing critical quality control solutions for regulated applications across pharmaceutical, healthcare, and medical device industries, focusing on product integrity, patient safety, and worker safety.
Mesa Laboratories (NASDAQ:MLAB) has announced a quarterly dividend declaration of $0.16 per share of common stock. The dividend will be distributed on June 16, 2025, to shareholders recorded as of May 30, 2025.
Mesa Labs, a global leader in life science tools and critical quality control solutions, serves the pharmaceutical, healthcare, and medical device industries. The company focuses on ensuring product integrity, increasing patient and worker safety, and improving quality of life worldwide through their specialized products and services.
Mesa Laboratories (NASDAQ:MLAB) reported strong Q3 FY2025 results with revenues increasing 17.5% to $62,840,000. The company achieved 13.2% core organic revenue growth and an 8,725% increase in operating income to $5,779,000. Despite operational improvements, Mesa reported a net loss of $1,676,000 primarily due to unrealized foreign currency losses and interest expense.
Performance across divisions showed positive momentum: Sterilization and Disinfection Control (37% of revenues) grew 8.2% core organic, Calibration Solutions (23%) achieved 18.9% growth, Biopharmaceutical Development (20%) saw 31.3% growth, and Clinical Genomics (20%) posted 1.9% growth. The company reduced its debt by $9.4M during the quarter, lowering its Total Net Leverage Ratio to 3.20, with a target to reduce it below 3.0x by end of Q2 2026.
Mesa Laboratories (NASDAQ:MLAB) has announced it will release its third quarter fiscal year 2025 financial results on Tuesday, February 4, 2025, at approximately 8:00 A.M. Eastern time. Mesa Labs is a global leader specializing in life science tools and critical quality control solutions for regulated applications across pharmaceutical, healthcare, and medical device industries. Their products and services focus on ensuring product integrity, enhancing patient and worker safety, and improving global quality of life.
Mesa Laboratories (NASDAQ:MLAB) has announced its Board of Directors' declaration of a regular quarterly dividend of $0.16 per share of common stock. The dividend will be paid on March 17, 2025, to shareholders of record as of the close of business on February 28, 2025.
Mesa Labs operates as a global leader in designing and manufacturing life science tools and critical quality control solutions, primarily serving regulated applications in the pharmaceutical, healthcare, and medical device industries. Their products and services aim to ensure product integrity, enhance patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) reported Q2 FY2025 results with revenues increasing 8.8% to $57,833,000, primarily driven by 11% growth from the GKE acquisition. Operating income surged 5,947% to $3,508,000, while net income increased 379%. The company experienced a 2.8% decline in core organic revenues. Notable division performance included Sterilization and Disinfection Control (38% of revenues) declining 5.2% in core organic growth, while Biopharmaceutical Development showed strong growth of 27.9%. The company reduced its debt by $7,438,000, bringing the Net Leverage Ratio to 3.26.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
Mesa Labs is a global leader in designing and manufacturing life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company's products and services aim to ensure product integrity, increase patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) reported strong Q1 FY2025 results, with revenues increasing 14.9% to $58,170,000 and core organic revenues growth of 3.0%. Operating income surged 940%, while non-GAAP adjusted operating income excluding unusual items rose 47.0% to $15,341,000 or 26.4% of revenues. The company saw growth across most divisions, with Biopharmaceutical Development leading at 23.5% core organic growth. However, Clinical Genomics faced headwinds in China and North America. Mesa Labs repaid $9.4 million in debt, reducing its Net Leverage Ratio to 3.41. The company remains focused on driving profitability and reducing debt, aiming for a ratio below 3.0x.